ABCL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abcellera Biologics Inc (ABCL) is not a strong buy at the moment given the investor's long-term strategy and beginner knowledge level. While the company has shown significant revenue growth, its declining net income and EPS, coupled with neutral technical indicators and lack of positive catalysts, suggest that this is not an optimal entry point. The options data also indicates bearish sentiment, and there are no recent signals from Intellectia Proprietary Trading Signals to support a buy decision.
The MACD is slightly positive at 0.083, but contracting, indicating weakening momentum. RSI is neutral at 58.149, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 3.414, with resistance at 3.747 and support at 3.082. Overall, the technical indicators are neutral, offering no strong buy signal.
The company's revenue increased significantly by 788.18% YoY in Q4 2025, and the gross margin remains strong at 100%.
Net income dropped by 73.85% YoY, and EPS declined by 75.00% YoY, reflecting profitability concerns. No recent news or significant trading trends from hedge funds or insiders. Options data suggests bearish sentiment, and no recent congress trading activity was recorded.
In Q4 2025, revenue surged to $44.85M (up 788.18% YoY), but net income fell to -$8.95M (-73.85% YoY), and EPS dropped to -0.03 (-75.00% YoY). Gross margin remains strong at 100%, but profitability remains a concern.
No recent analyst ratings or price target changes were provided. Wall Street sentiment is unclear, with no strong pros or cons view available.
